Margarida Maia, PhD,  science writer—

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

Immune signatures may predict MS course, treatment response

Researchers have identified three distinct immune signatures in the blood of people with early multiple sclerosis (MS) that seem to be linked to specific disease trajectories and response to treatment, potentially offering a path to personalized care. “These findings represent a pivotal shift towards precision medicine in MS,” Heinz Wiendl,…

Common MS therapies appear safe to use while breastfeeding

Taking antibody-based medications for multiple sclerosis (MS) while breastfeeding does not appear to harm a child’s health or development during at least the first three years of life, according to a preliminary study of more than 180 babies. Children breastfed by mothers taking Tysabri (natalizumab), Ocrevus (ocrelizumab),…

Complement protein activation is linked to more severe MS

Complement proteins, especially when activated in the brain and spinal cord, may contribute to nerve cell damage and more severe multiple sclerosis (MS) symptoms, a study that offers insights into a possible therapeutic target suggests. The study, “Complement Activation Is Associated With Disease Severity in Multiple Sclerosis,” was…

Compassion-focused therapy eases thoughts about suicide, pain

Engaging in online sessions of compassion-focused therapy, which works toward getting people to become more compassionate about themselves, may help women with multiple sclerosis (MS) deal with suicidal thoughts, a small study suggests. Compassion-focused therapy also may help these women overcome pain catastrophizing, which is a tendency to view…

Foralumab nasal spray shown to ease fatigue in nonactive SPMS

Six of eight patients with nonactive secondary progressive multiple sclerosis (SPMS) being treated with foralumab nasal spray — all part of an intermediate-size expanded access program (EAP) allowing the therapy’s use — have experienced reductions in their fatigue levels. That’s according to treatment developer Tiziana Life Sciences,…